Safeguard Scientifics, Inc. (SFES) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.51 means the share price is 0.51 times one year of earnings per share. Market cap $10.0M is the value of all shares combined. Beta 0.28: the stock has moved about 72% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSafeguard Scientifics, Inc. (SFES) trades at $0.6001. Safeguard Scientifics, Inc. is a private equity and venture capital firm that formerly specialized in providing expansion and growth financing to technology, financial services, and healthcare companies. Market cap: $10.0M, Sector: Financials.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for SFES: SFES does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Safeguard Scientifics, Inc. (SFES) Financial Services Profile
Safeguard Scientifics, Inc., based in Radnor, PA, is a private equity and venture capital firm focused on growth and expansion funding within the technology, financial services, and healthcare sectors. While historically active in early to growth-stage investments, the company is no longer making new investments as of 2026.
What Is the Investment Thesis for SFES?
Safeguard Scientifics, Inc. presents a complex investment case given its current state of no longer making new investments. With a market capitalization of $10.0M and a negative ROE of -36.0%, the company's financial performance raises concerns. The high debt-to-equity ratio of 6.25 indicates significant leverage. The company's beta of 0.28 suggests low volatility relative to the market. Investors should closely examine the company's existing portfolio and asset liquidation strategy. The absence of a dividend yield further reduces the attractiveness for income-seeking investors. Any potential value would likely stem from the strategic management of existing assets and the realization of value from its historical investments.
Based on FMP financials and quantitative analysis
SFES Key Highlights
Market capitalization of $10.0M indicates a small-cap company.
- Negative ROE of -36.0% reflects poor profitability and inefficient use of equity.
- Debt-to-equity ratio of 6.25 suggests high financial leverage.
- Free cash flow of $-0.00B indicates the company is not generating positive cash flow from operations.
- Beta of 0.28 suggests the stock is significantly less volatile than the market.
Who Are SFES's Competitors?
SFES is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| TPVG TriplePoint Venture Growth BDC Corp. | $3.63 | -1.89% | $148M | 75 5-pillar |
| AINV Apollo Investment Corporation | $13.65 | +0.59% | $893M | — |
| BXSL Blackstone Secured Lending Fund | $23.27 | -0.70% | $5.43B | — |
| BCG Binah Capital Group, Inc. | $1.81 | +11.04% | $30.9M | 78 5-pillar |
| PDPA Pearl Diver Credit Company Inc. | $24.85 | +0.41% | $50.5M | 55 5-pillar |
| HNNA Hennessy Advisors, Inc. | $9.97 | -1.38% | $78.8M | 79 5-pillar |
| SSEA Starry Sea Acquisition Corp | $10.54 | 0.00% | $80.4M | 48 5-pillar |
| SAMG Silvercrest Asset Management Group Inc. | $10.75 | -0.56% | $84.1M | 51 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SFES's Key Strengths?
Historical expertise in technology, financial services, and healthcare investing.
- Established network of industry contacts.
- Experience in providing value-added support to portfolio companies.
- Legacy of successful exits and value creation.
What Are SFES's Weaknesses?
No longer making new investments, limiting growth potential.
- Negative ROE indicates poor profitability.
- High debt-to-equity ratio increases financial risk.
- Small market capitalization limits access to capital.
What Could Drive SFES Stock Higher?
Potential sale of remaining portfolio companies.
- Cost reduction initiatives to improve profitability.
- Active management of existing assets to maximize returns.
What Are the Key Risks for SFES?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Economic downturn could negatively impact the value of portfolio companies.
- Limited liquidity in the OTC market could make it difficult to trade shares.
- Negative ROE indicates poor profitability and inefficient use of equity.
- High debt-to-equity ratio increases financial risk.
What Are the Growth Opportunities for SFES?
- Monetization of Existing Portfolio Companies: Safeguard Scientifics can focus on maximizing the value of its current portfolio companies through strategic sales or IPOs. The market for strategic acquisitions remains robust, particularly for companies with innovative technologies or strong market positions in high-growth sectors. Successful exits could provide significant returns and enhance shareholder value. The timeline for these exits depends on market conditions and the performance of the individual portfolio companies.
- Operational Efficiency Improvements: Streamlining operations and reducing overhead costs can improve profitability and free up capital. By implementing cost-cutting measures and optimizing resource allocation, Safeguard Scientifics can enhance its financial performance and increase its attractiveness to potential acquirers or strategic partners. This is an ongoing effort with potential for immediate impact on the company's bottom line.
- Strategic Partnerships and Alliances: Collaborating with other financial institutions or private equity firms can provide access to new markets, technologies, and investment opportunities. Strategic partnerships can also help to diversify risk and enhance the firm's competitive position. The timeline for forming strategic partnerships depends on identifying suitable partners and negotiating mutually beneficial agreements.
- Leveraging Intellectual Property: Safeguard Scientifics can explore opportunities to license or commercialize its intellectual property assets. This can generate additional revenue streams and enhance the value of its portfolio companies. The market for intellectual property licensing is growing, driven by increasing demand for innovative technologies and solutions. The timeline for commercializing intellectual property depends on the specific assets and market conditions.
- Restructuring and Recapitalization: Exploring options for restructuring its balance sheet and recapitalizing the company can improve its financial flexibility and reduce its debt burden. This may involve issuing new equity, refinancing existing debt, or selling non-core assets. A successful restructuring can enhance the company's long-term sustainability and create value for shareholders. The timeline for restructuring depends on market conditions and the company's financial situation.
What Threats Does SFES Face?
- Economic downturn could negatively impact the value of portfolio companies.
- Increased competition in the private equity and venture capital industry.
- Regulatory changes could impact investment strategies.
- Inability to successfully exit portfolio companies could lead to losses.
What Are SFES's Competitive Advantages?
- Historical expertise in identifying and nurturing high-growth companies.
- Established network of industry contacts and strategic partners.
- Proprietary knowledge and insights into emerging trends in technology, financial services, and healthcare.
- Reputation for providing value-added support to portfolio companies.
What Does SFES Do?
Safeguard Scientifics, Inc., established in 1953 as Lancaster Corporation and rebranded in 1981, transitioned into a private equity and venture capital firm. Headquartered in Radnor, Pennsylvania, with an additional office in Weston, Massachusetts, the firm historically focused on providing expansion financings, growth capital, management buyouts, recapitalizations, industry consolidations, corporate spinouts, and early-stage financings. Safeguard Scientifics primarily targeted companies in the technology, financial services, and healthcare sectors, initially investing in Series A-C rounds and opportunistically in seed rounds. Within technology, their focus included software as a service, adtech, digital media, Internet of Everything, enhanced security, predictive analytics, machine learning, artificial intelligence, enterprise software, technology-enabled services, fintech, cloud, mobile, social, big data, and in-memory computing. In healthcare, they targeted molecular and point-of-care diagnostics, medical devices, regenerative medicine, digital health, specialty pharmaceuticals, and selected healthcare services. Geographically, Safeguard Scientifics invested throughout the United States, with a concentration in the Mid-Atlantic region and Southeastern Canada. Typical investments ranged from $5 million to $25 million for growth equity and $5 million to $10 million for early-stage financing. The firm sought to be the largest shareholder, aiming for 20% to 50% ownership, and preferred companies with proprietary technology and intellectual property, often taking a board seat. As of 2026, Safeguard Scientifics, Inc. is no longer making new investments.
What Products and Services Does SFES Offer?
- Historically invested in technology, financial services, and healthcare companies.
- Provided expansion and growth financing to portfolio companies.
- Focused on Series A-C rounds and opportunistic seed rounds.
- Targeted companies with proprietary technology and intellectual property.
- Took board seats in portfolio companies to guide strategy.
- Sought ownership stakes between 20% and 50% in portfolio companies.
- No longer making new investments as of 2026.
How Does SFES Make Money?
- Historically generated returns through capital appreciation of portfolio companies.
- Realized gains through strategic sales, IPOs, or recapitalizations of portfolio companies.
- No longer generating revenue through new investments.
- Currently focused on managing existing assets and liquidating portfolio holdings.
What Industry Does SFES Operate In?
Safeguard Scientifics operates within the asset management industry, a sector characterized by intense competition and evolving investment strategies. The industry is influenced by macroeconomic trends, interest rate fluctuations, and technological advancements. Firms compete on investment performance, fees, and client service. Given Safeguard Scientifics' current position of no longer making new investments, its competitive focus has shifted to managing existing assets and maximizing returns from its legacy portfolio. The overall asset management industry continues to grow, driven by increasing wealth and demand for sophisticated investment solutions.
Who Are SFES's Key Customers?
- Early-stage and growth-stage companies in technology, financial services, and healthcare seeking capital.
- Entrepreneurs and management teams looking for strategic investors.
- Limited partners in Safeguard Scientifics' funds.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 4 purchases, 0 sales, 8 other transactions · 11 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
SFES Valuation & Market Position
With a $10.0M market cap, Safeguard Scientifics, Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for Safeguard Scientifics, Inc. stands at 130.9%, a gauge of how efficiently it converts shareholder capital into profit. SFES trades at a trailing price-to-earnings ratio of 0.51, below the Financial Services sector average of ~17.80x. A current ratio of 8.07 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Safeguard Scientifics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Safeguard Scientifics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-3.52.
Company Profile
Safeguard Scientifics, Inc. operates in the Asset Management industry within the Financial Services sector. It is headquartered in Radnor, US. The company is led by CEO Mark R. Dow. SFES has traded publicly since 1980.
SFES Financials
Bull Case vs Bear Case
Bull Case
- Historical expertise in technology, financial services, and healthcare investing.
- Established network of industry contacts.
- Experience in providing value-added support to portfolio companies.
- Legacy of successful exits and value creation.
Bear Case
- No longer making new investments, limiting growth potential.
- Negative ROE indicates poor profitability.
- High debt-to-equity ratio increases financial risk.
- Small market capitalization limits access to capital.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SFES Latest News
No recent news available for SFES.
SFES Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SFES.
Price Targets
Wall Street price target analysis for SFES.
SFES MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SFES; grades run from A+ (80-100) to F (below 30).
SFES OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Safeguard Scientifics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available and may be subject to greater price volatility and lower liquidity compared to exchange-listed stocks on NYSE or NASDAQ. Investing in OTC Other stocks carries a higher degree of risk due to the potential for less stringent regulatory oversight and reduced transparency.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads increase transaction costs.
- Potential for price manipulation and fraud is higher on the OTC market.
- Reduced regulatory oversight compared to exchange-listed stocks.
- Going concern risk due to the company no longer making new investments.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive position.
- Analyze the company's capital structure and debt obligations.
- Review the company's legal and regulatory filings.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Company has been in operation since 1953.
- Previously traded on a major exchange before moving to OTC.
- Headquartered in Radnor, Pennsylvania, with an additional office in Weston, Massachusetts.
- Focus on technology, financial services, and healthcare sectors.
Safeguard Scientifics, Inc. Financials Stock: Key Questions Answered
Is SFES a good stock to buy?
Stock Expert AI does not rate SFES buy, sell or hold. Safeguard Scientifics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SFES stock price today?
The last price recorded on this page for Safeguard Scientifics, Inc. (SFES) is $0.6001, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about SFES stock?
As of 2026, there is limited analyst coverage on Safeguard Scientifics, Inc. due to its small market capitalization and OTC listing.
What are the key factors to evaluate for SFES?
Evaluate SFES on fundamentals, analyst consensus, and risk factors. P/E: 0.51x. Safeguard Scientifics, Inc. presents a complex investment case given its current state of no longer making new investments. Not financial advice.
How frequently does SFES data refresh on this page?
SFES's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SFES's recent stock price performance?
Safeguard Scientifics, Inc. (SFES) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Historical expertise in technology, financial services, and healthcare investing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SFES overvalued or undervalued right now?
Safeguard Scientifics, Inc. (SFES) trades at 0.51x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SFES before investing?
Before investing in Safeguard Scientifics, Inc. (SFES), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.